» Articles » PMID: 20559039

Effect on Mortality and Virological Response of Delaying Antiretroviral Therapy Initiation in Children Receiving Tuberculosis Treatment

Overview
Journal AIDS
Date 2010 Jun 19
PMID 20559039
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To estimate the effect of delaying antiretroviral treatment (ART) for 15, 30, or 60 days after tuberculosis (TB) treatment initiation on mortality and virological suppression.

Design: Cohort of 573 ART-naive HIV-infected children initiated on TB treatment at an outpatient clinic in South Africa between April 2004 and March 2008.

Methods: Hazard ratios for mortality and viral suppression were estimated using marginal structural models and multivariate Cox models, respectively.

Results: During follow-up (median 9.64 months), 37 HIV-infected children died after a median of 62 days of TB treatment. ART was initiated in 461 children at a median of 17 days after TB treatment initiation, 415 (90%) achieved viral suppression. The hazard ratios of death for initiating ART more than 15, more than 30, or more than 60 days of TB treatment compared with initiating within 15, 30 and 60 days, respectively, were 0.82 (95% CI: 0.48, 1.41), 0.86 (95% CI: 0.46, 1.60), and 1.32 (95% CI: 0.55, 3.16). Hazard ratios for analysis restricted to severely immunosuppressed children were: 0.92 (95% CI: 0.51, 1.63), 1.08 (95% CI: 0.56, 2.08), and 2.23 (95% CI: 0.85, 5.80), respectively. Hazard ratios for viral suppression were 0.98 (95% CI: 0.76, 1.26), 0.95, (95% CI: 0.73, 1.23), 0.84 (95% CI: 0.61, 1.15), respectively and did not change with restriction to children severely immunosuppressed.

Conclusion: In this observational study, we found that delaying ART for 2 months or more in children diagnosed with TB may be associated with poorer virological response and increased mortality, particularly in children with severe immunosuppression. These findings should be confirmed in a randomized controlled trial.

Citing Articles

Success rates and adherence to antiretroviral therapy among treatment-naïve patients in Davao City, Philippines: A ten-year retrospective cohort study.

Escartin R, Servillon R, Legarta J, Arriola S, Brahim P, Braza D Dialogues Health. 2024; 5:100195.

PMID: 39398487 PMC: 11470175. DOI: 10.1016/j.dialog.2024.100195.


A systematic review of risk factors for mortality among tuberculosis patients in South Africa.

Nicholson T, Hoddinott G, Seddon J, Claassens M, van der Zalm M, Lopez E Syst Rev. 2023; 12(1):23.

PMID: 36814335 PMC: 9946877. DOI: 10.1186/s13643-023-02175-8.


The burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa: a systematic review and meta-analysis.

Adetokunboh O, Awotiwon A, Ndwandwe D, Uthman O, Wiysonge C Hum Vaccin Immunother. 2019; 15(11):2590-2605.

PMID: 30945963 PMC: 6930054. DOI: 10.1080/21645515.2019.1599676.


Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.

Harausz E, Garcia-Prats A, Law S, Schaaf H, Kredo T, Seddon J PLoS Med. 2018; 15(7):e1002591.

PMID: 29995958 PMC: 6040687. DOI: 10.1371/journal.pmed.1002591.


Getting to 90-90-90 in paediatric HIV: What is needed?.

Davies M, Pinto J, Bras M J Int AIDS Soc. 2017; 18(7Suppl 6):20770.

PMID: 28326130 PMC: 4813611. DOI: 10.7448/IAS.18.7.20770.


References
1.
Ren Y, Nuttall J, Egbers C, Eley B, Meyers T, Smith P . Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2008; 47(5):566-9. DOI: 10.1097/QAI.0b013e3181642257. View

2.
Elenga N, Kouakoussui K, Bonard D, Fassinou P, Anaky M, Wemin M . Diagnosed tuberculosis during the follow-up of a cohort of human immunodeficiency virus-infected children in Abidjan, Côte d'Ivoire: ANRS 1278 study. Pediatr Infect Dis J. 2005; 24(12):1077-82. DOI: 10.1097/01.inf.0000190008.91534.b7. View

3.
Violari A, Cotton M, Gibb D, Babiker A, Steyn J, Madhi S . Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008; 359(21):2233-44. PMC: 2950021. DOI: 10.1056/NEJMoa0800971. View

4.
Hernan M, Lanoy E, Costagliola D, Robins J . Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol. 2006; 98(3):237-42. DOI: 10.1111/j.1742-7843.2006.pto_329.x. View

5.
Kampmann B, Tena-Coki G, Nicol M, Levin M, Eley B . Reconstitution of antimycobacterial immune responses in HIV-infected children receiving HAART. AIDS. 2006; 20(7):1011-8. DOI: 10.1097/01.aids.0000222073.45372.ce. View